Latest Ipratropium Stories
REDWOOD CITY, Calif., June 16, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S.
WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today advised consumers not to use certain respiratory medications purchased after Sept.
Federal officials are warming consumers not to use certain respiratory medications purchased after Sept. 8, produced by Dey L.P., a subsidiary of Mylan Inc. The U.S.
NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc.
SAN DIEGO, May 19 /PRNewswire/ -- Data from two presentations highlighting the use of Perforomist(R) (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease (COPD) patients were featured today at the International Conference of the American Thoracic Society in San Diego.
NAPA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc.
- To fire mitraille at.